Your browser doesn't support javascript.
loading
Cognitive processes of apathy in Huntington's disease show high sensitivity to disease progression.
Hare, Emily; Bachoud-Lévi, Anne-Catherine; Reilmann, Ralf; Craufurd, David; Busse, Monica; Rosser, Anne; McLauchlan, Duncan.
Afiliación
  • Hare E; Cardiff University Neuroscience and Mental Health Research Institute, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.
  • Bachoud-Lévi AC; INSERM U 955, Institut Mondor de Recherche Biomédicale (IMRB), Cretéil, France.
  • Reilmann R; Hôpital Henri Mondor (Hôpitaux Universitaires Henri Mondor), Cretéil, France.
  • Craufurd D; George-Huntington-Institute, Technology-Park Muenster, Deilmann Building, Johann-Krane Weg 27, 48149 Muenster, Germany.
  • Busse M; Manchester Centre for Genomic Medicine, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PL, UK.
  • Rosser A; St. Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UK.
  • McLauchlan D; Cardiff University Neuroscience and Mental Health Research Institute, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.
Clin Park Relat Disord ; 7: 100168, 2022.
Article en En | MEDLINE | ID: mdl-36405870
ABSTRACT

Background:

Disease-modifying treatments for Huntington's disease (HD) are entering clinical trials there is a pressing need for objective outcome measures of disease progression. Our previous work showed an association between 2 novel, objective cognitive tasks and apathy - a core feature of disease progression in HD.

Objective:

Evaluate the longitudinal validity and sensitivity of the novel Persistence and Maze tasks to assess their utility as clinical outcome measures in HD.

Methods:

83 participants positive for the HD gene and 54 controls performed a battery of established and novel tools, at baseline and 12 month follow up.

Results:

The Maze task was found to be the most sensitive measure of change at 12 months, including the current gold-standard measure (the composite disease progression score).

Conclusion:

The Maze task has potential as a novel outcome measure of disease progression in HD and may have utility in other major neurodegenerative diseases.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Clin Park Relat Disord Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Clin Park Relat Disord Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
...